Kenya's government has paused plans for a U.S.-funded Ebola testing laboratory near Nairobi after protests erupted over the project, throwing into doubt tens of millions of dollars in foreign investment that regional markets had been counting on. The delay threatens to undermine confidence in Kenya's ability to host complex international health projects at a time when the country is competing for development funding from Washington.
What Sparked the Outcry
The proposed facility, backed by $50 million in U.S. Agency for International Development funding, was slated for construction in Kajiado County, a semi-arid region roughly 100 kilometres south of Nairobi. Local residents and politicians objected to what they described as a lack of consultation before land was identified for the project. Community leaders in Kajiado held three successive demonstrations over two weeks, with the latest protest on March 15 drawing more than 2,000 people, according to county officials.
The anger centred on two concerns: the absence of a formal environmental impact assessment, and fears that the facility could attract disease risks to the region rather than contain them. County Commissioner Joseph Okonjo told reporters on Tuesday that officials had received no advance notice from Nairobi about the project until reports surfaced in local media. "We learned about this from the newspapers," Okonjo said. "That is not how you treat a community."
The U.S. Position
The U.S. embassy in Nairobi confirmed the project was under discussion but declined to comment on the specific timeline. A spokesperson for USAID, speaking on condition of anonymity because the contract had not been finalised, said the facility was intended to strengthen disease surveillance across East Africa following the 2022 mpox outbreak that spread from West Africa. The United States has prioritised regional health security since losing an estimated $4.1 billion in trade during the Ebola crisis of 2014-2016, when multiple African nations imposed travel restrictions that crippled cross-border commerce.
Washington has been quietly expanding its health infrastructure footprint across sub-Saharan Africa, funding fourteen laboratories across six countries since 2019. Kenya has hosted three of those facilities, all without significant public resistance. The Kajiado project marks the first time a proposed U.S. health installation has faced organised popular opposition in the country.
Why Investors Are Taking Notice
For investors tracking Kenya's business climate, the protests signal a deeper problem. Several American companies operating in the country, including a Nairobi-based medical device distributor and a regional logistics firm with operations in Mombasa, have contacted the American Chamber of Commerce to express concern. They fear the episode could complicate future approvals for infrastructure projects that require community buy-in.
Kenya's shilling held steady at 153.40 against the dollar on Wednesday, but currency traders said the volatility risk premium on Kenyan assets had risen since the protests became public. "The market will watch how the government handles this," said one Nairobi-based forex analyst at a major international bank. "If it looks like political risk is increasing ahead of elections, that changes the calculus for foreign portfolio investors."
Health Officials Sound Alarm
The World Health Organization has not issued a statement on the Kenyan project specifically, but the organisation's Africa office in Brazzaville has repeatedly warned that delays in building regional disease-response capacity cost lives. Dr. Matshidiso Moeti, WHO's Africa director, told a Geneva briefing last month that every month of inaction during an outbreak window costs an estimated $200 million in broader economic damage across the continent.
Kenya's Ministry of Health issued a statement defending the project as "a critical investment in the nation's health security infrastructure." Cabinet Secretary Susan Nakhumicha said the facility would include biosafety Level 3 protocols, the standard used for handling serious pathogens including viral haemorrhagic fevers. She added that Kenya had hosted similar facilities without incident for more than a decade.
Political Fallout in Nairobi
The controversy has placed pressure on President William Ruto's administration, which has made attracting foreign investment a centrepiece of its economic recovery programme. Opponents in parliament have seized on the issue. Senator Jackson Mandago, who represents Uasin Gishu county, called for a parliamentary inquiry into how the project was awarded without competitive bidding. The Senate health committee has scheduled hearings for April 8.
Ruto's administration had been anticipating a joint announcement with U.S. officials in May, coinciding with Washington Summit discussions on Indo-Pacific security cooperation. That timeline now looks impossible. A government official close to the matter, speaking to The EastAfrican, said the administration was weighing whether to proceed with modifications to the site location or abandon the project entirely.
What Comes Next
The Kajiado County Assembly has passed a motion demanding a 90-day moratorium on all government land transfers for health infrastructure pending new legislation. That motion is not binding on Nairobi, but county officials say they will pursue legal action if the national government proceeds without their consent.
For South African businesses with interests in Kenyan trade, the standoff carries practical consequences. South Africa exported approximately $1.8 billion in goods to Kenya last year, with pharmaceutical products making up a significant share. Any disruption to Kenya's health infrastructure ambitions could reshape demand for medical imports from Johannesburg and Cape Town over the next two years.
USAID has not formally withdrawn its offer, but the agency has not responded to the county government's requests for a meeting since March 12. That silence is widening the trust gap between local communities and international development agencies that the protests exposed.
"The market will watch how the government handles this," said one Nairobi-based forex analyst at a major international bank. Kenya's Ministry of Health issued a statement defending the project as "a critical investment in the nation's health security infrastructure." Cabinet Secretary Susan Nakhumicha said the facility would include biosafety Level 3 protocols, the standard used for handling serious pathogens including viral haemorrhagic fevers.
